United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The EU is doubling its purchases of the Pfizer-BioNTech coronavirus vaccine at a time of growing concern over its rollout.

EU agrees new Pfizer Covid vaccine deal and secures nearly half its annual output

New York and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published on the preprint server bioRxiv and are available here.

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

The study is preliminary and has not yet been reviewed by experts, a key step for medical research.

Pfizer study suggests vaccine works against virus variant

Pfizer Inc (NYSE: PFE)/BionNTech SE (NASDAQ: BNTX) COVID-19 showed signs of working against a mutation found in two highly-contagious COVID-19 virus variants detected in the U.K. and South Africa in a laboratory study conducted by Pfizer. What Happened: These positive findings were spotted during the study, conducted in collaboration with the University of Texas Medical Branch, reports Reuters.

Pfizer Study Shows Vaccine Efficacious Against COVID-19 Variant

The COVID-19 vaccine from pharmaceutical companies Pfizer and BioNTech looks to be effective against 16 different mutations of the coronavirus, according to a study that has not yet undergone peer review. As Reuters reported, the study, by researchers at Pfizer and the University of Texas Medical Branch, suggests the vaccine will not need to be tweaked in order to work against a seemingly more contagious variant of the coronavirus that arose in the UK.

Early study suggests Pfizer vaccine effective against COVID-19 mutations

Preliminary data shows Pfizer's mRNA vaccine can effectively neutralize coronavirus variants in lab tests.

Pfizer vaccine appears effective against rapidly spreading coronavirus variants

A new coronavirus vaccine isn't the only reason to buy this big pharma stock right now.

Pfizer Stock: A Top Bet for 2021?

Amgen

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Merck

Verizon

Walgreens

Exxon Mobil

This not-so-old strategy of identifying undervalued blue chip stocks has had its moments -- but not enough of them.

The Dogs of the Dow Didn't Hunt in 2020, and 2021 Isn't Looking Much Better

Pfizer has a strong pipeline and an attractive dividend yield, making PFe stock attractive for certain types of investors. The post While It's Price Won't Soar, Pfizer Stock Is a Fantastic Long-Term Buy appeared first on InvestorPlace.

While It's Price Won't Soar, Pfizer Stock Is a Fantastic Long-Term Buy

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD). The CIFFREO trial is expected to enroll 99 ambulatory male patients, ages 4 through 7, across 55 clinical trial sites in 15 countries. The first patient was dosed at a site in Barcelona, Spain on December 29, 2020.

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T...

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Pfizer is trading at a remarkable 4.19% dividend yield. The analyst consensus is for a 12.48% price gain over the next twelve months.

Pfizer: Mr. Market Vs. The Analysts

A new brand identity aims to embody the pharma giant's shift from pills like Advil and Viagra to the science of vaccines. Pharmaceutical giant Pfizer has unveiled its most significant brand refresh in about 70 years.

Pfizer unveils its first major logo redesign in 70 years

The company "unlocks" its famous little blue pill in a symbolic move.

Pfizer Launches First Major Rebranding in Over 70 Years

Avantor Inc.

Becton, Dickinson and Co.

Johnson & Johnson

Moderna

Thermo Fisher Scientific

West Pharmaceutical Services

The Covid-19 vaccine rally isn't just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.

7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible

American Airlines

Alaska Air Group

AstraZeneca

Delta Air Lines

Southwest Airlines

United Continental Hlds

The availability of vaccines is likely to boost air travel in 2021. As a result, Delta (DAL), American Airlines (AAL), Southwest Airlines (LUV) and United Airlines (UAL) are likely to be aided by the uptick in passenger revenues.

Airlines End 2020 on a Solid Note: More Rally Awaited in 2021?

With the U.K. entering a third nationwide lockdown and the COVID-19 pandemic raging through the rest of Europe, vaccines approved for emergency use are in high demand.  What Happened: The European Union is negotiating with Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) to procure an additional 100 million doses of the pair's coronavirus vaccine candidate, with an option to buy 200 million more doses, according to a Bloomberg report.

EU In Talks To Buy Up To 300M More Coronavirus Vaccine Doses From Pfizer-BioNTech

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39th Annual J.P. Morgan Healthcare Conference to be held virtually. Albert Bourla, Chairman and Chief Executive Officer, will participate in a fireside chat presentation on Tuesday, January 12, 2021 at 10:00 a.m. EST. Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, will participate in a COVID-19 Vaccines Keynote Panel

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference

Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.

Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance

Johnson & Johnson and Pfizer are dependable stocks with good dividends, but they get little love from the market, making them bargains this year.

2 Undervalued Stocks for 2021

Boeing

Salesforce

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2021 Dogs of the Dow

The United States Food and Drug Administration has warned against changing the dosing regimen, interval, or mixing of COVID-19 vaccines in a statement issued Monday. What Happened: The health agency recognized that available data indicates the use of two specified doses of the COVID-19 vaccines — made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) — at specified intervals.

FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments

Tesla

Tech Finishes as the Strongest Sector in 2020

OPKO Health

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). The target Prescription Drug User Fee Act (PDUFA) action date for decision by the FDA is in O

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

ICON

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, today announced it provided clinical trial services to the Pfizer (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) investigational COVID-19 vaccine programme. Pfizer and BioNTech were the first to announce positive efficacy results from a Phase 3, la

News for Pfizer Stock (PFE)